Ms. Heidi Sue Haney, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 140 Poplar Street, Powers, OR 97466 Phone: 541-439-7884 Fax: 541-439-3225 |
News Archive
GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
In this week's PLoS Medicine magazine, Yibeltal Assefa, from the National HIV/AIDS Prevention and Control Office in Addis Ababa, and colleagues describe the successes and challenges of the scale-up of antiretroviral treatment (ART) across Ethiopia.
BioBehavioral Diagnostics (BioBDx), a privately held company which manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of attention-deficit hyperactivity disorder (ADHD), announced today the first close of a $10 million Series B financing.
The European Society for Medical Oncology and the American Society of Clinical Oncology, the world's two leading organizations for oncology professionals, today issued a joint statement calling upon governments to renew political commitment to improve cancer services and reduce cancer deaths.
› Verified 3 days ago